Imaging Studies in Patients with Melanoma

Surgical Oncology Clinics of North America

Volumn 16, Issue 2, 2007, Pages 403-430

  Choi, Eugene A ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER INCIDENCE; CANCER STAGING; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; IMAGING SYSTEM; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PEROPERATIVE CARE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; RECURRENT CANCER; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN METASTASIS; THORAX RADIOGRAPHY; TREATMENT PLANNING;

ALGORITHMS; DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; HUMANS; INTRAOPERATIVE CARE; MAGNETIC RESONANCE IMAGING; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PREOPERATIVE CARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34249887912     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.03.004     Document Type: Review

References (65)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 16 (2001) 3635-3648
3. Houghton A.N., Coit D.G., Daud A., et al. Melanoma. J Natl Compr Canc Netw 4 7 (2006) 666-684
4. Virgo K.S., Chan D., Handler B.S., et al. Current practice of patient follow-up after potentially curative resection of cutaneous melanoma. Plast Reconstr Surg 106 3 (2000) 590-597
5. Johnson T.M., Bradford C.R., Gruber S.B., et al. Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol 140 1 (2004) 107-113
6. Hofmann U., Szedlak M., Rittgen W., et al. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 87 2 (2002) 151-157
7. Garbe C., Paul A., Kohler-Spath H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21 3 (2003) 520-529
8. Dicker T.J., Kavanagh G.M., Herd R.M., et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 140 2 (1999) 249-254
9. Poo-Hwu W.J., Ariyan S., Lamb L., et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86 11 (1999) 2252-2258
10. Terhune M.H., Swanson N., and Johnson T.M. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 134 5 (1998) 569-572
11. Khansur T., Sanders J., and Das S.K. Evaluation of staging workup in malignant melanoma. Arch Surg 124 7 (1989) 847-849
12. Ardizzoni A., Grimaldi A., Repetto L., et al. Stage I-II melanoma: the value of metastatic work-up. Oncology 44 2 (1987) 87-89
13. Wang T.S., Johnson T.M., Cascade P.N., et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 51 3 (2004) 399-405
14. Mooney M.M., Mettlin C., Michalek A.M., et al. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 80 6 (1997) 1052-1064
15. Buzaid A.C., Sandler A.B., Mani S., et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11 4 (1993) 638-643
16. Buzaid A.C., Tinoco L., Ross M.I., et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 13 8 (1995) 2104-2108
17. Kuvshinoff B.W., Kurtz C., and Coit D.G. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 4 3 (1997) 252-258
18. Muller-Horvat C., Radny P., Eigentler T.K., et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 42 3 (2006) 342-350
19. Fogarty G.B., and Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin Oncol (R Coll Radiol) 18 4 (2006) 360-362
20. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 3 (1999) 976-983
21. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 4 (1992) 392-399
22. Miranda E.P., Gertner M., Wall J., et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 139 8 (2004) 831-836 [discussion: 836-37]
23. Aloia T.A., Gershenwald J.E., Andtbacka R.H., et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 24 18 (2006) 2858-2865
24. Lassau N., Mercier S., Koscielny S., et al. Prognostic value of high-frequency sonography and color Doppler sonography for the preoperative assessment of melanomas. AJR Am J Roentgenol 172 2 (1999) 457-461
25. Serrone L., Solivetti F.M., Thorel M.F., et al. High frequency ultrasound in the preoperative staging of primary melanoma: a statistical analysis. Melanoma Res 12 3 (2002) 287-290
26. Rossi C.R., Mocellin S., Scagnet B., et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 83 2 (2003) 80-84
27. Voit C., Kron M., Schafer G., et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 13 12 (2006) 1682-1689
28. Voit C., Mayer T., Kron M., et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 91 12 (2001) 2409-2416
29. Blum A., Schlagenhauff B., Stroebel W., et al. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer 88 11 (2000) 2534-2539
30. Solivetti F.M., Di Luca Sidozzi A., Pirozzi G., et al. Sonographic evaluation of clinically occult in-transit and satellite metastases from cutaneous malignant melanoma. Radiol Med (Torino) 111 5 (2006) 702-708
31. Basler G.C., Fader D.J., Yahanda A., et al. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol 36 3 Pt 1 (1997) 403-408
32. Kaufmann P.M., and Crone-Munzebrock W. [Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. Aktuelle Radiol 2 2 (1992) 81-85 [in German]
33. Health Care Financing Administration. Decision memorandum posted concerning Medicare coverage of FDG positron emission tomography. 2000.
34. Franc B.L., Mari C., Johnson D., et al. The role of a positron and high energy gamma probe in intraoperative localization of recurrent melanoma. Clin Nucl Med 30 12 (2000) 787-789
35. Steinert H.C., Huch Boni R.A., Buck A., et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 195 3 (1995) 705-709
36. Wagner J.D., Schauwecker D., Hutchins G., et al. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64 3 (1997) 181-189
37. Damian D.L., Fulham M.J., Thompson E., et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 6 4 (1996) 325-329
38. Prichard R.S., Hill A.D., Skehan S.J., et al. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89 4 (2002) 389-396
39. Swetter S.M., Carroll L.A., Johnson D.L., et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9 7 (2002) 646-653
40. Macfarlane D.J., Sondak V., Johnson T., et al. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 16 5 (1998) 1770-1776
41. Mijnhout G.S., Hoekstra O.S., van Lingen A., et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 56 4 (2003) 283-286
42. Mijnhout G.S., Hoekstra O.S., van Tulder M.W., et al. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 91 8 (2001) 1530-1542
43. Tyler D.S., Onaitis M., Kherani A., et al. Positron emission tomography scanning in malignant melanoma. Cancer 89 5 (2000) 1019-1025
44. Gulec S.A., Faries M.B., Lee C.C., et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 28 12 (2003) 961-965
45. Kokoska M.S., Olson G., Kelemen P.R., et al. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck Surg 125 3 (2001) 213-220
46. Fink A.M., Holle-Robatsch S., Herzog N., et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 14 2 (2004) 141-145
47. Havenga K., Cobben D.C., Oyen W.J., et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 29 8 (2003) 662-664
48. Holder Jr. W.D., White Jr. R.L., Zuger J.H., et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227 5 (1998) 764-769 [discussion: 769-71]
49. Wagner J.D., Schauwecker D., Davidson D., et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104 3 (2005) 570-579
50. Belhocine T.Z., Scott A.M., Even-Sapir E., et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 47 6 (2006) 957-967
51. Acland K.M., O'Doherty M.J., and Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 42 4 (2000) 606-611
52. Acland K.M., Healy C., Calonje E., et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 19 10 (2001) 2674-2678
53. Wagner J.D., Schauwecker D., Davidson D., et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17 5 (1999) 1508-1515
54. Brady M.S., Akhurst T., Spanknebel K., et al. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 13 4 (2006) 525-532
55. Friedman K.P., and Wahl R.L. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 34 4 (2004) 242-253
56. Rinne D., Baum R.P., Hor G., et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82 9 (1998) 1664-1671
57. Dietlein M., Krug B., Groth W., et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 20 3 (1999) 255-261
58. Eigtved A., Andersson A.P., Dahlstrom K., et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27 1 (2000) 70-75
59. Wagner J.D., Schauwecker D.S., Davidson D., et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 77 4 (2001) 237-242
60. Schafer A., Herbst R.A., Beiteke U., et al. [Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients]. Hautarzt 54 5 (2003) 440-447 [in German]
61. Longo M.I., Lazaro P., Bueno C., et al. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 29 3 (2003) 245-248
62. Hafner J., Schmid M.H., Kempf W., et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 150 4 (2004) 677-686
63. Reinhardt M.J., Joe A.Y., Jaeger U., et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24 7 (2006) 1178-1187
64. Iagaru A., Quon A., Johnson D., et al. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 9 1 (2007) 50-57
65. Pawlik T.M., Erasmus J.J., Truong M.T., et al. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol 187 1 (2006) W117-W119